CytoMed Therapeutics Limited (NASDAQ:GDTC) Short Interest Up 31.1% in December

CytoMed Therapeutics Limited (NASDAQ:GDTC) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 82,200 shares, a growth of 31.1% from the December 15th total of 62,700 shares. Currently, 1.7% of the shares of the stock are short sold. Based on an average trading volume of 195,600 shares, the short-interest ratio is currently 0.4 days.

CytoMed Therapeutics Trading Down 0.4 %

GDTC traded down $0.01 during trading on Friday, reaching $2.38. 17,375 shares of the company traded hands, compared to its average volume of 581,052. CytoMed Therapeutics has a 12-month low of $1.20 and a 12-month high of $4.30. The firm has a fifty day simple moving average of $2.57 and a 200 day simple moving average of $2.13.

Wall Street Analyst Weigh In

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $5.00 price objective on shares of CytoMed Therapeutics in a research note on Thursday, October 10th.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.